Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Report Overview
Friedreich’s Ataxia (FRDA) is a rare, genetic disorder. It is progressive and typically manifests between the ages of 10 and 15. The disorder is characterized by a gradual decline in coordination, muscle strength, and endurance. Individuals with FRDA often become reliant on wheelchairs as the condition advances.
The Friedreich Ataxia (FRDA) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Friedreich Ataxia.
The report also provides actionable insights into the clinical and commercial landscapes of Friedreich Ataxia (FRDA)drugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
Key Mechanisms of Action (Pipeline) | · Enzyme Activator
· Enzyme Replacement · Enzyme Inhibitor · Protein & Peptide Activator · Protein & Peptide Inhibitor |
Key Molecule Types (Pipeline) | · Small Molecule
· Gene Therapy · Gene-Modified Cell Therapy · Recombinant Protein · Cell Therapy |
Top Sponsors (Marketed and Pipeline Drugs) | · Biogen Inc
· Larimar Therapeutics Inc · PTC Therapeutics Inc · Neurocrine Biosciences Inc · Design Therapeutics Inc |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Friedreich Ataxia (FRDA) Pipeline Drugs Market Segmentation by Mechanisms of Action
The key MoA of the drugs in the Friedreich Ataxia (FRDA) pipeline mainly includes enzyme activator, enzyme replacement, enzyme inhibitor, protein & peptide activator, and protein & peptide inhibitor among others. Most of the pipeline drugs undergoing development for FRDA followed enzyme activator MoA in 2023.
Friedreich Ataxia (FRDA) Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of Friedreich Ataxia (FRDA) Pipeline Drugs
Friedreich Ataxia (FRDA) Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types for Friedreich Ataxia (FRDA) pipeline drugs were small molecule, gene therapy, gene-modified cell therapy, recombinant protein, and cell therapy among others. The small molecule was the leading molecule type in 2023.
Friedreich Ataxia (FRDA) Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of Friedreich Ataxia (FRDA) Pipeline Drugs
Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Market – Competitive Landscape
A few of the top sponsors in the Friedreich Ataxia (FRDA) marketed and pipeline drugs market are Biogen Inc., Larimar Therapeutics Inc., PTC Therapeutics Inc., Neurocrine Biosciences Inc., and Design Therapeutics Inc. among others. Biogen Inc. sponsored the highest number of trials in 2023.
Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy the Full Report for More Sponsor Insights into the Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Market
Segments Covered in the Report
Friedreich Ataxia (FRDA) Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Enzyme Activator
- Enzyme Replacement
- Enzyme Inhibitor
- Protein & Peptide Activator
- Protein & Peptide Inhibitor
Friedreich Ataxia (FRDA) Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Small Molecule
- Gene Therapy
- Gene-Modified Cell Therapy
- Recombinant Protein
- Cell Therapy
Scope
The key components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Understand the trends shaping and driving the Friedreich Ataxia (FRDA)market to develop business strategies.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Friedreich Ataxia (FRDA)market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which was the leading MoA for Friedreich Ataxia (FRDA) pipeline drugs in 2023?
Most of the drugs followed enzyme activator MoA in 2023 in the Friedreich Ataxia (FRDA) drugs market.
-
Which was the leading molecule type for Friedreich Ataxia (FRDA) pipeline drugs in 2023?
In 2023, most of the drugs in development for Friedreich Ataxia (FRDA) were small molecules.
-
Which are the top sponsors in the Friedreich Ataxia (FRDA) marketed and pipeline drugs market?
A few of the top sponsors in the Friedreich Ataxia (FRDA) marketed and pipeline drugs market are Biogen Inc., Larimar Therapeutics Inc., PTC Therapeutics Inc., Neurocrine Biosciences Inc., and Design Therapeutics Inc. among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.